schliessen

Filtern

 

Bibliotheken

Development and prospective multicenter evaluation of the long noncoding RNA MALAT-1 as a diagnostic urinary biomarker for prostate cancer

The current strategy for diagnosing prostate cancer (PCa) is mainly based on the serum prostate-specific antigen (PSA) test. However, PSA has low specificity and has led to numerous unnecessary biopsies. We evaluated the effectiveness of urinary metastasis-associated lung adenocarcinoma transcript 1... Full description

Journal Title: Oncotarget 30 November 2014, Vol.5(22), pp.11091-102
Main Author: Wang, Fubo
Other Authors: Ren, Shancheng , Chen, Rui , Lu, Ji , Shi, Xiaolei , Zhu, Yasheng , Zhang, Wei , Jing, Taile , Zhang, Chao , Shen, Jian , Xu, Chuanliang , Wang, Huiqing , Wang, Haifeng , Wang, Yang , Liu, Bin , Li, Yaoming , Fang, Ziyu , Guo, Fei , Qiao, Meng , Wu
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: E-ISSN: 1949-2553 ; PMID: 25526029 Version:1
Link: http://pubmed.gov/25526029
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: medline25526029
title: Development and prospective multicenter evaluation of the long noncoding RNA MALAT-1 as a diagnostic urinary biomarker for prostate cancer
format: Article
creator:
  • Wang, Fubo
  • Ren, Shancheng
  • Chen, Rui
  • Lu, Ji
  • Shi, Xiaolei
  • Zhu, Yasheng
  • Zhang, Wei
  • Jing, Taile
  • Zhang, Chao
  • Shen, Jian
  • Xu, Chuanliang
  • Wang, Huiqing
  • Wang, Haifeng
  • Wang, Yang
  • Liu, Bin
  • Li, Yaoming
  • Fang, Ziyu
  • Guo, Fei
  • Qiao, Meng
  • Wu
subjects:
  • Biomarkers, Tumor -- Urine
  • Prostatic Neoplasms -- Urine
  • RNA, Long Noncoding -- Urine
ispartof: Oncotarget, 30 November 2014, Vol.5(22), pp.11091-102
description: The current strategy for diagnosing prostate cancer (PCa) is mainly based on the serum prostate-specific antigen (PSA) test. However, PSA has low specificity and has led to numerous unnecessary biopsies. We evaluated the effectiveness of urinary metastasis-associated lung adenocarcinoma transcript 1 (MALAT-1), a long noncoding RNA, for predicting the risk of PCa before biopsy. The MALAT-1 score was tested in a discovery phase and a multi-center validation phase. The predictive power of the MALAT-1 score was evaluated by the area under receiver operating characteristic (ROC) curve (AUC) and by decision curve analysis. As an independent predictor of PCa, the MALAT-1 score was significantly higher in men with a positive biopsy than in those with a negative biopsy. The ROC analysis showed a higher AUC for the MALAT-1 score (0.670 and 0.742) vs. the total PSA (0.545 and 0.601) and percent free PSA (0.622 and 0.627) in patients with PSA values of 4.0-10 ng/ml. According to the decision curve...
language: eng
source:
identifier: E-ISSN: 1949-2553 ; PMID: 25526029 Version:1
fulltext: fulltext
issn:
  • 19492553
  • 1949-2553
url: Link


@attributes
ID1433001214
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid25526029
sourceidmedline
recordidTN_medline25526029
sourceformatXML
sourcesystemPC
pqid1639496781
display
typearticle
titleDevelopment and prospective multicenter evaluation of the long noncoding RNA MALAT-1 as a diagnostic urinary biomarker for prostate cancer
creatorWang, Fubo ; Ren, Shancheng ; Chen, Rui ; Lu, Ji ; Shi, Xiaolei ; Zhu, Yasheng ; Zhang, Wei ; Jing, Taile ; Zhang, Chao ; Shen, Jian ; Xu, Chuanliang ; Wang, Huiqing ; Wang, Haifeng ; Wang, Yang ; Liu, Bin ; Li, Yaoming ; Fang, Ziyu ; Guo, Fei ; Qiao, Meng ; Wu
ispartofOncotarget, 30 November 2014, Vol.5(22), pp.11091-102
identifierE-ISSN: 1949-2553 ; PMID: 25526029 Version:1
subjectBiomarkers, Tumor -- Urine ; Prostatic Neoplasms -- Urine ; RNA, Long Noncoding -- Urine
descriptionThe current strategy for diagnosing prostate cancer (PCa) is mainly based on the serum prostate-specific antigen (PSA) test. However, PSA has low specificity and has led to numerous unnecessary biopsies. We evaluated the effectiveness of urinary metastasis-associated lung adenocarcinoma transcript 1 (MALAT-1), a long noncoding RNA, for predicting the risk of PCa before biopsy. The MALAT-1 score was tested in a discovery phase and a multi-center validation phase. The predictive power of the MALAT-1 score was evaluated by the area under receiver operating characteristic (ROC) curve (AUC) and by decision curve analysis. As an independent predictor of PCa, the MALAT-1 score was significantly higher in men with a positive biopsy than in those with a negative biopsy. The ROC analysis showed a higher AUC for the MALAT-1 score (0.670 and 0.742) vs. the total PSA (0.545 and 0.601) and percent free PSA (0.622 and 0.627) in patients with PSA values of 4.0-10 ng/ml. According to the decision curve...
languageeng
source
version3
lds50peer_reviewed
links
openurl$$Topenurl_article
backlink$$Uhttp://pubmed.gov/25526029$$EView_this_record_in_MEDLINE/PubMed
openurlfulltext$$Topenurlfull_article
addlink$$Uhttp://exlibris-pub.s3.amazonaws.com/aboutMedline.html$$EView_the_MEDLINE/PubMed_Copyright_Statement
search
creatorcontrib
0Wang, Fubo
1Ren, Shancheng
2Chen, Rui
3Lu, Ji
4Shi, Xiaolei
5Zhu, Yasheng
6Zhang, Wei
7Jing, Taile
8Zhang, Chao
9Shen, Jian
10Xu, Chuanliang
11Wang, Huiqing
12Wang, Haifeng
13Wang, Yang
14Liu, Bin
15Li, Yaoming
16Fang, Ziyu
17Guo, Fei
18Qiao, Meng
19Wu, Chengyao
20Wei, Qiang
21Xu, Danfeng
22Shen, Dan
23Lu, Xin
24Gao, Xu
25Hou, Jianguo
26Sun, Yinghao
titleDevelopment and prospective multicenter evaluation of the long noncoding RNA MALAT-1 as a diagnostic urinary biomarker for prostate cancer
descriptionThe current strategy for diagnosing prostate cancer (PCa) is mainly based on the serum prostate-specific antigen (PSA) test. However, PSA has low specificity and has led to numerous unnecessary biopsies. We evaluated the effectiveness of urinary metastasis-associated lung adenocarcinoma transcript 1 (MALAT-1), a long noncoding RNA, for predicting the risk of PCa before biopsy. The MALAT-1 score was tested in a discovery phase and a multi-center validation phase. The predictive power of the MALAT-1 score was evaluated by the area under receiver operating characteristic (ROC) curve (AUC) and by decision curve analysis. As an independent predictor of PCa, the MALAT-1 score was significantly higher in men with a positive biopsy than in those with a negative biopsy. The ROC analysis showed a higher AUC for the MALAT-1 score (0.670 and 0.742) vs. the total PSA (0.545 and 0.601) and percent free PSA (0.622 and 0.627) in patients with PSA values of 4.0-10 ng/ml. According to the decision curve...
subject
0Biomarkers, Tumor -- Urine
1Prostatic Neoplasms -- Urine
2RNA, Long Noncoding -- Urine
general
025526029
1English
2MEDLINE/PubMed (U.S. National Library of Medicine)
3MEDLINE/PubMed (NLM)
sourceidmedline
recordidmedline25526029
issn
019492553
11949-2553
rsrctypearticle
creationdate2014
addtitleOncotarget
searchscope
0medline
1nlm_medline
2MEDLINE
scope
0medline
1nlm_medline
2MEDLINE
lsr4120141130
citationpf 11091 vol 5 issue 22
startdate20141130
enddate20141130
lsr30VSR-Enriched:[pages, doi, pqid]
sort
titleDevelopment and prospective multicenter evaluation of the long noncoding RNA MALAT-1 as a diagnostic urinary biomarker for prostate cancer
authorWang, Fubo ; Ren, Shancheng ; Chen, Rui ; Lu, Ji ; Shi, Xiaolei ; Zhu, Yasheng ; Zhang, Wei ; Jing, Taile ; Zhang, Chao ; Shen, Jian ; Xu, Chuanliang ; Wang, Huiqing ; Wang, Haifeng ; Wang, Yang ; Liu, Bin ; Li, Yaoming ; Fang, Ziyu ; Guo, Fei ; Qiao, Meng ; Wu
creationdate20141130
lso0120141130
facets
frbrgroupid4898974554396581389
frbrtype5
newrecords20190701
languageeng
creationdate2014
topic
0Biomarkers, Tumor–Urine
1Prostatic Neoplasms–Urine
2RNA, Long Noncoding–Urine
collectionMEDLINE/PubMed (NLM)
prefilterarticles
rsrctypearticles
creatorcontrib
0Wang, Fubo
1Ren, Shancheng
2Chen, Rui
3Lu, Ji
4Shi, Xiaolei
5Zhu, Yasheng
6Zhang, Wei
7Jing, Taile
8Zhang, Chao
9Shen, Jian
10Xu, Chuanliang
11Wang, Huiqing
12Wang, Haifeng
13Wang, Yang
14Liu, Bin
15Li, Yaoming
16Fang, Ziyu
17Guo, Fei
18Qiao, Meng
19Wu, Chengyao
20Wei, Qiang
21Xu, Danfeng
22Shen, Dan
23Lu, Xin
24Gao, Xu
25Hou, Jianguo
26Sun, Yinghao
jtitleOncotarget
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Wang
1Ren
2Chen
3Lu
4Shi
5Zhu
6Zhang
7Jing
8Shen
9Xu
10Liu
11Li
12Fang
13Guo
14Qiao
15Wu
16Wei
17Gao
18Hou
19Sun
aufirst
0Fubo
1Shancheng
2Rui
3Ji
4Xiaolei
5Yasheng
6Wei
7Taile
8Chao
9Jian
10Chuanliang
11Huiqing
12Haifeng
13Yang
14Bin
15Yaoming
16Ziyu
17Fei
18Meng
19Chengyao
20Qiang
21Danfeng
22Dan
23Xin
24Xu
25Jianguo
26Yinghao
au
0Wang, Fubo
1Ren, Shancheng
2Chen, Rui
3Lu, Ji
4Shi, Xiaolei
5Zhu, Yasheng
6Zhang, Wei
7Jing, Taile
8Zhang, Chao
9Shen, Jian
10Xu, Chuanliang
11Wang, Huiqing
12Wang, Haifeng
13Wang, Yang
14Liu, Bin
15Li, Yaoming
16Fang, Ziyu
17Guo, Fei
18Qiao, Meng
19Wu, Chengyao
20Wei, Qiang
21Xu, Danfeng
22Shen, Dan
23Lu, Xin
24Gao, Xu
25Hou, Jianguo
26Sun, Yinghao
atitleDevelopment and prospective multicenter evaluation of the long noncoding RNA MALAT-1 as a diagnostic urinary biomarker for prostate cancer
jtitleOncotarget
risdate20141130
volume5
issue22
spage11091
pages11091-11102
issn1949-2553
eissn1949-2553
formatjournal
genrearticle
ristypeJOUR
abstractThe current strategy for diagnosing prostate cancer (PCa) is mainly based on the serum prostate-specific antigen (PSA) test. However, PSA has low specificity and has led to numerous unnecessary biopsies. We evaluated the effectiveness of urinary metastasis-associated lung adenocarcinoma transcript 1 (MALAT-1), a long noncoding RNA, for predicting the risk of PCa before biopsy. The MALAT-1 score was tested in a discovery phase and a multi-center validation phase. The predictive power of the MALAT-1 score was evaluated by the area under receiver operating characteristic (ROC) curve (AUC) and by decision curve analysis. As an independent predictor of PCa, the MALAT-1 score was significantly higher in men with a positive biopsy than in those with a negative biopsy. The ROC analysis showed a higher AUC for the MALAT-1 score (0.670 and 0.742) vs. the total PSA (0.545 and 0.601) and percent free PSA (0.622 and 0.627) in patients with PSA values of 4.0-10 ng/ml. According to the decision curve...
pmid25526029
doi10.18632/oncotarget.2691
date2014-11-30